Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Strong points include growth in Personal Health and order strength in North America. However, uncertainties like tariff impacts, cautious guidance, and vague responses about future margins dampen positivity. The absence of a market cap makes it difficult to predict strong reactions. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Key Financial Performance
Order Intake Grew 6% in Q2 2025, building on 9% growth last year. Reasons include broad-based growth across most regions, double-digit growth in North America, and strong performance in growth geographies.
Comparable Sales Increased by 1% in Q2 2025. Growth in Personal Health offset declines in Diagnosis & Treatment (D&T) and Connected Care. Decline in China impacted overall growth.
Adjusted EBITA Margin Expanded by 130 basis points to 12.4% in Q2 2025. Reasons include productivity measures, improved gross margin from innovation, favorable mix effect, and operational efficiency. Partially offset by advertising and promotion spend, cost inflation, and lower sales in China.
Free Cash Flow EUR 230 million in Q2 2025, driven by higher earnings but offset by working capital outflows due to seasonal phasing.
Diagnosis & Treatment (D&T) Sales Decreased by 1% in Q2 2025 due to a high 2-year comparison base. Image-Guided Therapy showed solid performance, while Precision Diagnosis sales declined slightly due to a high comparison base in magnetic resonance.
D&T Adjusted EBITA Margin Improved by 130 basis points to 13.5% in Q2 2025. Reasons include contributions from innovations like BlueSeal MR and Azurion Neuro Biplane, productivity measures, and operational efficiency. Partially offset by cost inflation.
Connected Care Sales Declined by 1% in Q2 2025, mainly due to a low single-digit decline in Monitoring. High 2-year comparison base impacted results.
Connected Care Adjusted EBITA Margin Improved by 160 basis points to 10.4% in Q2 2025. Reasons include productivity measures, operational efficiency, and a low comparable base. Partially offset by cost inflation.
Personal Health Sales Strong growth in Q2 2025 across most geographies, offset by a decline in China due to inventory destocking. Supported by new innovations and partnerships with major retailers.
Personal Health Adjusted EBITA Margin Declined by 170 basis points to 15.2% in Q2 2025. Reasons include mix, cost inflation, and advertising and promotion spend to support recent launches.
Savings from Productivity Initiatives EUR 197 million in Q2 2025, contributing to a year-to-date total of EUR 344 million. Driven by product simplification, SKU reduction, and operational efficiency.
Adjusted Diluted EPS EUR 0.36 in Q2 2025, up 20% year-over-year, benefiting from improved gross margin.
Net Debt Approximately EUR 6.6 billion at the end of Q2 2025, with a leverage ratio of 2.2x on a net debt-to-adjusted EBITA basis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Azurion Neuro Biplane R3: This innovation is driving double-digit year-on-year order growth and contributing to higher win rates across all Biplane systems.
Helium-free BlueSeal MRI system: The only commercially available wide-bore 1.5T helium-free system, saving 1,500 liters of helium per system, reducing installation costs, and offering flexibility in facility placement.
MR SmartSpeed Precise Dual AI software: FDA-cleared AI solution delivering 3x faster scanning and up to 80% sharper images.
CT 5300 and Spectral CT 7500: AI-enabled systems accounting for over half of all CT order intake value, demonstrating clinical and operational impact.
AI-powered i9000 electric shaver and Sonicare toothbrushes: Recent launches supported by advertising and promotion spend to drive long-term demand.
North America: Double-digit order intake growth driven by strong demand for innovations in Diagnosis & Treatment and Connected Care.
Indonesia: Nationwide agreement to expand access to image-guided therapy using Azurion platform, benefiting millions of patients.
China: Market dynamics remain cautious despite stimulus activity and increased tender activity.
India and Saudi Arabia: Investments in healthcare infrastructure and digitalization represent high-growth opportunities.
Quality management improvements: Simplified and strengthened quality management system, reducing field actions and product updates by 20% year-to-date.
Supply chain reliability: Service levels reached an all-time high of 86%, improving speed and reliability of product delivery.
Productivity savings: Achieved EUR 344 million in savings year-to-date, on track for EUR 800 million in 2025.
Tariff mitigation actions: Optimizing inventory locations, supplier networks, and manufacturing to enhance cost efficiency.
New operating model: Reducing complexity and aligning resources to growth areas, contributing to productivity improvements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impact: The company faces a dynamic tariff landscape, with tariffs on U.S.-China bilateral trade and imports from the EU into the U.S. impacting costs. Despite mitigation efforts, the tariff impact is expected to be more pronounced in the second half of 2025, potentially affecting adjusted EBITA margins and free cash flow.
China Market Challenges: The company continues to face subdued consumer sentiment and inventory destocking in China, leading to a decline in sales. Stimulus activity and tender activity are increasing but from a low base, and no significant change in market dynamics has been observed.
Cost Inflation: Cost inflation, including the initial impact of increased tariffs, is partially offsetting productivity measures and operational efficiency improvements, impacting margins across segments.
Respironics-Related Costs: Ongoing costs related to Respironics field-action and consent decree remediation remain a financial burden, with EUR 54 million incurred in Q2 2025. These costs are expected to continue impacting financials.
Supply Chain Challenges: While supply chain reliability has improved, the company continues to face challenges in maintaining agility and mitigating tariff impacts, which require ongoing operational focus and adjustments.
High Comparison Base: Segments like Diagnosis & Treatment and Connected Care are facing challenges due to high comparison bases from prior years, impacting sales growth.
Advertising and Promotion Costs: Increased advertising and promotion spending to support new product launches and long-term demand generation is pressuring margins, particularly in the Personal Health segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Comparable Sales Growth: Reiterated at 1% to 3%, with greater weighting towards the fourth quarter.
Adjusted EBITA Margin: Increased to a range of 11.3% to 11.8%, reflecting a 50 basis points improvement due to recent tariff developments.
Free Cash Flow: Expected to range between EUR 0.2 billion and EUR 0.4 billion for the full year, up from slightly positive previously.
Order Book and Sales Outlook: Order momentum and robust order book provide clear visibility into second half sales conversion, supporting the full year sales outlook.
Diagnosis & Treatment and Connected Care Segments: Positioned to accelerate growth and margin in the second half of the year due to strong order book and increasing momentum.
Personal Health Segment: Sales momentum expected to drive accelerated growth in the second half, supported by strong traction from new innovations and partnerships.
Tariff Impact: Estimated net impact for 2025 is between EUR 150 million and EUR 200 million, down approximately EUR 100 million from the previous estimate.
Q3 and Q4 Projections: Q3 comparable sales projected to be slightly above the full year range of 1% to 3%, with further improvement anticipated in Q4.
Capital Markets Day: Scheduled for February 2026 to outline the next phase of strategy, focusing on mid-single-digit growth and mid-teens margins beyond 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the improvement in D&T margins and the underlying expansion here?
A:The D&T margin expanded by 130 basis points, driven by gross margin expansion due to innovations like BlueSeal MR, Spectral CT 7500, and Azurion Neuro Biplane. Additional factors include productivity improvements, portfolio simplification, SKU reduction, and favorable mix impacts from solid IGT sales and increased services portfolio contributions.
Q:Why have you only banked the tariff improvement and not the EBITA beat in the quarter?
A:Management highlighted conservatism in their approach, noting that while they are pleased with the tariff improvements, they need to accelerate margin expansion in the second half of the year to meet guidance. They also cited potential FX headwinds and the tariff impact hitting the P&L in the second half.
Q:Can you unpack the decline in Connected Care in the quarter by segment, particularly monitoring in S&RC?
A:Connected Care sales declined by 1%, driven by a low single-digit drop in Monitoring. This decline follows strong growth in 2023 and reflects a high base. Despite this, demand for Monitoring solutions remains strong, with six major partnerships concluded in the U.S. Respironics and SoC performance slowed due to a strong pickup last year, but momentum in masks and reentry into the market is positive.
Q:Where are you in the European market on the system side versus where you were prior to the recall, in share terms?
A:Management stated it is too early to provide specific market share numbers but noted they are rebuilding momentum and expanding in European markets, with customers welcoming them back.
Q:How far did the destocking for Personal Health in China complete in the quarter?
A:The destocking program in China was completed in the second quarter. Management noted strong sell-out momentum, supported by campaigns like the 18/6 festival, where they ranked #1 on JD.com in their category.
Q:What are you seeing in terms of medical equipment tenders in China and how is that translating into orders and revenues?
A:Tenders are slowly recovering, with a competitive and prolonged process. Management expects improvement in the second half, albeit from a low base and at a slow pace. They remain cautious but see structural improvement in the longer term.
Q:Should we annualize the tariff impact for 2026 based on the second half of 2025?
A:Management has incorporated the new tariff reality into their trajectory for mid-single-digit growth and mid-teens margins beyond 2025. They have established a SWAT team to address tariff scenarios.
Q:Can you elaborate on the strength in Personal Health and its sustainability?
A:Personal Health saw high-single to low-double-digit growth in Europe and the U.S., driven by innovations like the i9000 shaver and Sonicare midrange products. Growth is broad-based across regions, with China expected to pick up in the second half. Management remains cautious but confident in sustained demand.
Q:Can you elaborate on the order strength and regional performance?
A:Order strength was broad-based, with double-digit growth in IGT and high single-digit growth in PD. North America showed strong performance, and innovations like the Neuro Biplane and BlueSeal MR contributed significantly. Connected Care also showed strong momentum, particularly in North America.
Q:How much of the advertising and promotional spend in Personal Health was in price, and what are the pricing dynamics?
A:Advertising and promotional spend was focused on marketing campaigns, particularly in China, to drive sell-out. Pricing in Personal Health remained broadly flat, with no reductions to gain market share.
Q:How are U.S. hospitals thinking about the market in 2026?
A:U.S. hospitals are focusing on productivity and ambulatory solutions to serve more patients at lower costs. Management sees continued strong demand and is confident in their ability to support customers with innovations.
Q:Can you provide further color on the growth in Ultrasound revenue and D&T performance excluding China?
A:Ultrasound revenue slightly declined but is expected to strengthen in the second half due to strong order intake growth. D&T performance was diluted by China but is improving, with positive contributions expected in the second half.
Q:Are you still taking market share in Monitoring, particularly in the U.S.?
A:Yes, management noted strong momentum in Monitoring, with six major deals in North America and continued expansion into new markets.
Q:How far along are you in the SKU reduction process in D&T, and which businesses are most impacted?
A:The SKU reduction process is multiyear and on track, with progress across all D&T modalities, including Ultrasound, IGT, and MR. Initial impacts are seen in reduced complexity and improved productivity.
Q:What parts of the current strategy are working well, and where is there room for improvement?
A:Management highlighted improvements in patient safety, quality, supply chain, and organizational productivity. They aim to expand profitable growth through innovation and operational efficiency, with a focus on scalable platforms and margin expansion.
Q:Is there restocking in China in Q3, and how confident are you in delivering sales growth in H2?
A:There is no restocking in Q3; stock levels are aligned with sell-out. Management is confident in delivering flat to low single-digit sales growth in H2, supported by strengthening sell-out momentum.
Q:What is your level of confidence in achieving mid- to high-teens margins beyond 2025?
A:Management is confident in margin expansion through growth, mix improvements, and continued productivity measures. They acknowledge inflation and tariffs as factors but see ample opportunities for improvement.
Q:Was the large order with Indonesia included in Q2 order intake, and how significant was it?
A:The Indonesia order was included in Q2 order intake but contributed only partially due to its multiyear nature. The strongest order intake growth came from North America and other segments.
Q:What is the overall momentum in China at the group level, and how should we think about H2?
A:China had a negative first half but is expected to turn positive in H2, contributing slightly to the full-year plan. The majority of growth will come from other regions.
Q:Can the adjusted EBITA for the Other business line turn structurally positive in the future?
A:Management does not foresee significant shifts in the Other business line, as it includes innovation central costs and royalty income, which are subject to phasing.
Q:Review of Unclear Management Responses
A:Management avoided providing specific market share numbers for the European system market post-recall, citing it as too early to call. Additionally, they used vague language regarding mid- to high-teens margins beyond 2025, focusing on general opportunities without concrete details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Azurion Neuro
Customer
DT Connected
Europe geography
Health EBITA
Hospital Patient
Inc Research
MR
North America
Patient Monitoring
Research Division
advertising promotion
agreement
care infrastructure
comparison
flow EUR
geography decline
inflation
information
innovation order
inventory
measure efficiency
mitigation action
order book
partner
point productivity
product simplification
region
resource constraint
response
team
PHG Transcript
Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary indicates strong order intake, sales growth, and a strategic focus on North America and international regions, with positive EBITDA margin expectations. The Q&A section highlights strong growth in the sleep business, effective cost mitigation strategies, and positive innovation momentum. Although there are challenges like cost inflation and centralized procurement in China, Philips appears well-positioned to manage these with AI and pricing strategies. Overall, the sentiment is positive, suggesting a potential stock price increase in the near term.
Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call reflects a mixed outlook: strong order growth and margin improvements indicate potential positives, but uncertainties around tariffs and vague management responses about future challenges temper enthusiasm. The Q&A reveals concerns about flat growth in China and potential headwinds from tariffs. The financial performance and strategic updates are not strong enough to drive a significant stock movement, thus a neutral sentiment is appropriate.
Koninklijke Philips N.V. (PHG) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary indicates strong financial performance with increased EPS, productivity savings, and positive sales growth, particularly in Personal Health. The Q&A section reveals effective strategies for mitigating risks, such as tariff impacts and competition in China. The company's cautious but optimistic outlook, combined with strategic partnerships and ongoing innovations, supports a positive sentiment. Despite some uncertainties, the overall tone is positive, suggesting a likely stock price increase in the short term.
Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call presents a mixed outlook. Strong points include growth in Personal Health and order strength in North America. However, uncertainties like tariff impacts, cautious guidance, and vague responses about future margins dampen positivity. The absence of a market cap makes it difficult to predict strong reactions. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
PHG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
